The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla's product portfolio spans complex generics as well as drugs in the respiratory anti-retroviral urology cardiolo... In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure ...

Cipla is currently valued at Rs 1480.00, indicating a daily change of 1.09%. The 5-day exponential moving average stands at Rs 1470.50. Cipla is currently trading at Rs 1477.7, reflecting a positive ...

The domestic market saw a 7% rise in sales, driven by gains in cardiac, oncology, and dermatology therapies, even as anti-infective and respiratory drugs underperformed. Nuvama found that Sun Pharma, ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

Medical Dialogues team had earlier reported that Cipla Limited had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

And how much does it really cost to bring a drug to market? Increasingly, though, these debates are happening when everyone knows that the list price is not the ‘real’ price to be paid ...

So before, that used to be… marijuana used to be on the drug list, and they took that off a couple [of] years ago.” This marks a significant shift in WWE's wellness policy, reflecting the ...

Despite successful models in a few parts of India where regulated access to opioids has been implemented safely, there ...